News – Page 1158 – Endpoints News

Kite gives itself a little more time to finish FDA application for KTE-C19

9 years ago

Biopharma shares rally as Donald Trump scores a stunning upset

9 years ago

As election storm gathered, Arrowhead drops word about a clinical hold

9 years ago

Prop 61 goes down in flames, torching a national drug price control model

9 years ago

CureVac grabs a $29.5M round to fuel its mRNA development efforts

9 years ago

Can AI accelerate drug R&D? J&J offers up some molecules to try it on

9 years ago

Stanford team preps first human CRISPR study for sickle cell disease cure; Shkreli fingers his former attorneys

9 years ago

Versant’s global biotech team is reloading with $350M-plus fund

9 years ago

Cardio event forces FDA to halt a Penn PhII study for multiple myeloma

9 years ago

It’s Endpoints News' issue #100: The new daily biotech pub now has a little history

9 years ago

Cardio drug at The Medicines Co gets the heave-ho. (But they prefer PCSK9 anyway.)

9 years ago

Therapix Bio in the hunt for $12M micro IPO; Progenics bags $50M loan; Juno isn't going anywhere, for now

9 years ago

Roche flags early success for Tecentriq combos, hustles into PhIIIs

9 years ago

Public combat over US drug prices centers on Prop 61 as rhetoric heats up to fever pitch

9 years ago

Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data

9 years ago

Syncona, CRUK and BACIT join forces to create a $1.2B biotech investment powerhouse

9 years ago

In a squeaker, FDA AdComm votes for an OK of Cempra’s antibiotic

9 years ago

Alnylam spells out just why it scrapped revusiran following patient deaths; Innocoll shares plunge on PhIII flops

9 years ago

Hillary Clinton's War on Pharma II; A call for common sense reporting on Alzheimer's R&D

9 years ago

Sanofi jumps into a pivotal study for next-gen Pompe drug

9 years ago

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

9 years ago

Clinton’s chief strategist urged tough drug stance that aimed straight for the "cost pain point”

9 years ago

FDA officials: There was “no scientific basis” for Duchenne drug OK as Sarepta complained of “dire financial” ...

9 years ago

Celyad chief blasts Cellectis’ CEO Choulika, claiming he lied about CAR-T patent

9 years ago

First page Previous page 1155 1156 115711581159 1160 1161 Next page Last page